Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?

Journal of Urology

Volumn 157, Issue 6, 1997, Pages 2201-2205

  Drew, Peter A ^a   Murphy, William M ^a   Kubilis, Paul S ^a   Areford, Matthew ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

androgens; carcinoma; prostate; prostatic neoplasms

Indexed keywords

GONADORELIN AGONIST; LEUPRORELIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0030939288     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64717-7     Document Type: Article

References (14)

1. Civantos, F., Marcial, M. A., Banks, E. R., Ho, C. K., Speights, V. O., Drew, P. A., Murphy, W. M. and Soloway, M. S.: Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer, 75: 1634, 1995.
2. Montironi, R., Magi-Galluzzi, C., Muzzonigro, G., Prete, E., Polito, M. and Fabris, G.: Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J. Clin. Path., 47: 906, 1994.
3. Têtu, B., Srigley, J. R., Boivin, J. C., Dupont, A., Monfette, G., Pinault, S. and Labrie, F.: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Amer. J. Surg. Path., 15: 111, 1991.
4. Murphy, W. M., Soloway, M. S. and Barrows, G. H.: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer, 68: 821, 1991.
5. Smith, D. M. and Murphy, W. M.: Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer, 73: 1472, 1994.
6. Goldstein, N. S., Begin, L. R., Grody, W. W., Novak, J. M., Qian, J. and Bostwick, D. G.: Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the "vanishing cancer phenomenon." Amer. J. Surg. Path., 19: 1002, 1995.
7. Gleason, D. F., Mellinger, G. T. and the Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58, 1974.
8. Beahrs, O. H., Henson, D. E., Hutter, R. V. P. and Kennedy, B. J.: American Joint Committee on Cancer Manual for Staging of Cancer. Philadelphia: J. B. Lippincott Co., pp. 181-186, 1992.
9. Bauer, J. C.: Statistical Analysis for Decision Makers in Health-care. Chicago: Irwin, p. 117, 1996.
10. Bland, M.: An Introduction to Medical Statistics. Oxford: Oxford University Press, pp. 251-254, 1987.
11. Armitage, P. and Berry, G.: Statistical Methods in Medical Research, 3rd ed. Oxford: Blackwell Scientific Publications, pp. 443-447, 1994.
12. Ingelfinger, J. A., Mosteller, F., Thibodeau, L. A. and Ware, J. H.: Biostatistics in Clinical Medicine. New York: McGraw-Hill, pp. 316-322, 1994.
13. Ferguson, J., Bostwick, D. G., Ellison, E., Bergstralh, E. and Zincke, H.: Decrease in prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology, 44: 91, 1994.
14. Montironi, R., Muzzonigro, G., Magi-Galluzzi, C., Giannulis, I., Diamanti, L. and Polito, M.: Effect of LH-RH agonist and flutamide (combination endocrine therapy) on proliferating cell nuclear antigen and apoptotic bodies in prostatic hyperplasia. J. Urol. Path., 2: 161, 1994.